Avatrombopag for low platelets after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have a very low platelet count (below 20 × 10^9/L) or need platelet transfusions by day 7 after your stem cell transplant
- You agree to take avatrombopag and sign a consent form
- You do not have an active infection, serious liver or kidney problems, or a history of blood clots or heart disease
- You have not used other platelet-boosting medicines (like rhTPO or eltrombopag) in the last 2 weeks
- You are not pregnant, breastfeeding, or planning a pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug hetrombopag can safely raise platelet counts in people with immune thrombocytopenia (ITP) before they have surgery. The goal is to reduce bleeding risk during and after the operation.
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.